Target Deconvolution | Contract Research Organization

Drug Target Deconvolution

Greater precision for more transformative drug discovery

Identifying the target of a therapeutic compound is key to gaining deeper insights into its mechanism of action and potential toxicities. By applying Limited Proteolysis Mass Spectrometry (LiP-MS ), our Drug Target Deconvolution service offers a unique way to optimize and de-risk your drug discovery journey.

    Select any of the below topic preferences: By submitting this form, you confirm that you agree to the processing of your personal data by Biognosys as described in the Privacy Notice.

      Select any of the below topic preferences: By submitting this form, you confirm that you agree to the processing of your personal data by Biognosys as described in the Privacy Notice.

      Description

      LiP-MS is a novel, label-free approach to identifying on- and off-target binding effects throughout the proteome. It is the only tool to probe protein structural alterations on a proteome scale with peptide-level resolution. As a result, the Drug Target Deconvolution service offers a proteome coverage of up to 9000 proteins in human cells and a high depth of target ID.

       

      The study report will provide you with ranked protein target candidates for rapid target deconvolution and streamlined target validation.

       

      Biognosys is the sole, exclusive provider of proteomics solutions based on the patented LiP-MS technology developed in collaboration with the group of Prof. Paola Picotti at ETH Zurich.

      “We had previously enlisted other methods for target deconvolution and validation for our molecular glue program at the global protein structural readout level, including small molecule selectivity in cells. Biognosys’ TrueTargetTM (LiP-MS) platform provided a proteome-wide picture of our glue with peptide-level resolution. Analogous to HDX-MS on recombinant proteins, TrueTarget® (LiP-MS) simultaneously provided information about conformational changes and small molecule binding sites in cells within one experiment. With Biognosys’ high-quality data and bioinformatics support, we could draw conclusions about endogenous target binding and compound selectivity, moving our program forward with high confidence.”

      Maria Stella Ritorto, PhD
      Director of Proteomics at Nested Therapeutics, Cambridge, MA

       

      “The LiP technology is a very valuable tool to identify target and off-target of novel compounds whatever the organism and to support the process of target deconvolution in research. The interactions with Biognosys are very nice and fruitful. The team is engaged and responsive throughout the project.”

      Thomas Knobloch,
      Laboratory Manager, Bayer

      Resources

      Filter By

      Deliverables

      The results are presented and discussed with you in a seminar or webinar and delivered electronically in PDF and Excel formats that contain:

      Executive Summary
      Materials and Methods
      (suitable for publication)
      Complete Data Matrix

      Dose response curves for LiP peptides from protein candidates

      Target Deconvolution Analysis

      a) Protein target candidates ranked by aggregate LiP score

      b) Compound affinity concentration for each protein candidate

      c) Mapping of regulated peptides of top 3 candidates on protein tertiary structures, if available

      Sample types and depths

      Drug Target Deconvolution is applicable to complex biological matrices, including a wide variety of cell lines and organisms.

      SAMPLE REQUIREMENTS

      Project management

      Biognosys is committed to providing the best possible results to our customers at the fastest possible project turnaround time.

      WORKING WITH US

      Contact

        Close banner

        New: Spectronaut® 19

        Unlock Your Data's True Story

        New: Spectronaut® 19

        Unlock Your Data's True Story

        Learn More